Explore the vast range of titles available.

For the finishing of some difficult-to-machine materials, such as silicon carbide, diamond, and so on, a novel polishing technique named plasma-assisted polishing (PAP) was proposed, which combined with the irradiation of atmospheric pressure water vapor plasma and polishing using soft abrasives. In this article, application of PAP to 4H-SiC (0001) substrate was conducted. We used helium-based water vapor plasma to modify the mechanical and chemical properties of the SiC surface. The results of X-ray photoelectron spectroscopy measurements indicate that the surface was efficiently oxidized after plasma irradiation, and the main product was SiO 2 . CeO 2 was used as the abrasive material in PAP, the hardness of which was near to that of the oxidized surface. The scanning white light interferometer images of the PAP processed surface showed us that scratches disappeared and surface roughness also decreased from 4.410 nm p-v, 0.621 nm root mean square (rms) to 1.889 nm p-v, 0.280 nm rms. From the atomic force microscopy images, step and terrace structure was observed on the surface after PAP, which means an atomically flat surface was obtained. The PAP processed surface was observed using cross-sectional transmission electron microscope, which indicated that almost no crystallographical defects were introduced.

•A single dose of edaravone oral suspension was well absorbed by patients with ALS.•Edaravone oral suspension is mainly eliminated in urine as glucuronide conjugate.•Pharmacokinetic findings were similar with oral or PEG tube administration.•There were no safety concerns with oral or PEG tube administration of edaravone.•Edaravone can be administered orally and via PEG tube to patients with ALS. Edaravone is a neuroprotective agent approved as an intravenous treatment for amyotrophic lateral sclerosis (ALS). The intravenous administration of edaravone places a burden on patients and there is a clinical need for oral agents for the treatment of ALS. This report aimed to assess the pharmacokinetics and safety of an edaravone oral suspension in patients with ALS after oral and percutaneous endoscopic gastrostomy (PEG) tube administration. Two single-dose, open-label phase 1 clinical studies were conducted. Edaravone oral suspension (105 mg of edaravone in 5 mL aqueous suspension) was administered orally and via PEG tube to 9 and 6 Japanese patients with ALS, respectively. Plasma and urinary pharmacokinetics of unchanged edaravone and its metabolites (sulfate and glucuronide conjugates) were determined. Safety was also evaluated. After reaching maximum plasma concentration, the mean plasma concentration–time of unchanged edaravone showed a triphasic elimination. Mean plasma concentration–time profiles of the metabolites were higher than those of unchanged edaravone. The mean urinary excretion ratios were higher for the glucuronide conjugate than for either unchanged edaravone or the sulfate conjugate. In patients administered edaravone orally, a single adverse event occurred (blood urine present), which was mild and improved without medical intervention. No adverse drug reactions or serious adverse events were reported. In patients administered edaravone via PEG tube, 5 treatment-emergent adverse events were reported in 3 patients; none were related to the study drug. No adverse drug reactions were reported. In patients with ALS, a single dose of edaravone oral suspension was well absorbed and mainly eliminated in urine as the glucuronide conjugate. No safety concerns emerged. Pharmacokinetics were similar to those previously reported in healthy participants following oral administration. This indicates that effective drug concentrations were achieved and edaravone can be successfully administered both orally and via a PEG tube in patients with ALS. ClinicalTrials.gov, NCT04176224 (oral administration) and NCT04254913 (PEG tube administration), www.clinicaltrials.gov.

In a previous phase 3 study in patients with amyotrophic lateral sclerosis (ALS), edaravone did not show a significant difference in the Revised ALS Functional Rating Scale (ALSFRS-R) score compared with placebo. Post-hoc analysis of these data revealed that patients in an early stage with definite or probable diagnosis of ALS, defined by the revised El Escorial criteria, who met a select set of inclusion criteria showed a greater magnitude of effect than did the full study population. We aimed to substantiate this post-hoc result and assess safety and efficacy of edaravone in a phase 3 trial that focused on patients with early stage ALS who met the post-hoc analysis inclusion criteria. In this phase 3, randomised, double-blind, parallel-group study, patients aged 20–75 years with ALS of grade 1 or 2 in the Japan ALS Severity Classification, scores of at least 2 points on all 12 items of ALSFRS-R, forced vital capacity of 80% or more, definite or probable ALS according to the revised El Escorial criteria, and disease duration of 2 years or less were recruited from 31 hospitals in Japan. Eligible patients also had a decrease of 1–4 points in the ALSFRS-R score during a 12-week observation period before randomisation. Patients meeting all criteria were then randomly assigned 1:1 to receive 60 mg intravenous edaravone or intravenous saline placebo for 6 cycles (4 weeks per cycle with 2 weeks on, 2 weeks off) for a total treatment duration of 24 weeks. In cycle 1, the study drug or placebo was administered once per day for 14 days within a 14 day period, followed by the drug-free period. In cycle 2 and thereafter, the study drug or placebo was administered for 10 days within a 14 day period, followed by a 2 week drug-free period. Participants and investigators, including those assessing outcomes, were masked to treatment allocation. The primary efficacy outcome was the change in ALSFRS-R score from the baseline to 24 weeks (or at discontinuation if this was after the third cycle) after randomisation. The primary outcome was assessed in all patients who had received at least one treatment infusion, had at least one assessment post-baseline, and reached the end of cycle 3. For patients with missing values at the end of cycle 6, data were imputed by the last observation carried forward (LOCF) method, provided the patients had completed at least cycle 3. Safety was assessed in all patients who had received at least one treatment infusion and had at least one assessment post-baseline. This trial is registered with ClinicalTrials.gov, NCT01492686. Between Nov 28, 2011, and Sept 3, 2014, we screened 213 patients, and enrolled 192 as potential participants. Of these, 137 patients completed the observation period: 69 were randomly assigned to receive edaravone, and 68 were randomly assigned to receive placebo. 68 patients taking edaravone and 66 taking placebo were included in the primary efficacy analysis. For the primary outcome, the change in ALSFRS-R score was −5·01 (SE 0·64) in the edavarone group and −7·50 (0·66) in the placebo group. The least-squares mean difference between groups was 2·49 (SE 0·76, 95% CI 0·99–3·98; p=0·0013) in favour of edaravone. Treatment-emergent adverse events were reported in 58 (84%) patients receiving edaravone and 57 (84%) patients receiving placebo. 11 (16%) patients taking edaravone and 16 (24%) taking placebo had serious adverse events, and one (1%) patient receiving edaravone and four (6%) patients receiving placebo had adverse events (one dysphagia in edaravone group and one dyspnoea, two respiratory disorder, and one rash in the placebo group) that led to withdrawal. Edaravone showed efficacy in a small subset of people with ALS who met criteria identified in post-hoc analysis of a previous phase 3 study, showing a significantly smaller decline of ALSFRS-R score compared with placebo. There is no indication that edaravone might be effective in a wider population of patients with ALS who do not meet the criteria. Mitsubishi Tanabe Pharma Corporation.

Extraction of gold from electronic waste was commonly conducted using aqua regia. Here, we have shown a method to produce chloroauric acid in a salt solution by bipolar AC electrolysis. The developed bipolar AC electrolysis method provides an environment-friendly process to extract gold from electronic waste containing gold without using any strong acids such as aqua regia. 

We present measurements of the soft X-ray background emission for 130 Suzaku observations at \\(75^\\circ15^\\circ\\) obtained from 2005 to 2015, covering nearly one solar cycle. In addition to the standard soft X-ray background model consisting of the local hot bubble and the Milky Way Halo (MWH), we include a hot collisional-ionization-equilibrium component with a temperature of \\(\\sim 0.8\\) keV to reproduce spectra of a significant fraction of the lines of sight. Then, the scatter in the relation between the emission measure vs. temperature of the MWH component is reduced. Here, we exclude time ranges with high count rates to minimize the effect of the solar wind charge exchange (SWCX). However, the spectra of almost the same lines of sight are inconsistent. The heliospheric SWCX emissions likely contaminate and gives a bias in measurements of temperature and the emission measure of the MWH. Excluding the data around the solar maximum and using the data taken before the end of 2009, at \\(|b|>35^\\circ\\) and \\(105^\\circ

Paper

Share this book

Add to My Shelf